Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Pivotal role of cardiomyocyte TGF-β signaling in the murine pathological response to sustained pressure overload
Norimichi Koitabashi, … , Eiki Takimoto, David A. Kass
Norimichi Koitabashi, … , Eiki Takimoto, David A. Kass
Published May 2, 2011
Citation Information: J Clin Invest. 2011;121(6):2301-2312. https://doi.org/10.1172/JCI44824.
View: Text | PDF
Research Article Cardiology

Pivotal role of cardiomyocyte TGF-β signaling in the murine pathological response to sustained pressure overload

  • Text
  • PDF
Abstract

The cardiac pathological response to sustained pressure overload involves myocyte hypertrophy and dysfunction along with interstitial changes such as fibrosis and reduced capillary density. These changes are orchestrated by mechanical forces and factors secreted between cells. One such secreted factor is TGF-β, which is generated by and interacts with multiple cell types. Here we have shown that TGF-β suppression in cardiomyocytes was required to protect against maladaptive remodeling and involved noncanonical (non–Smad-related) signaling. Mouse hearts subjected to pressure overload and treated with a TGF-β–neutralizing Ab had suppressed Smad activation in the interstitium but not in myocytes, and noncanonical (TGF-β–activated kinase 1 [TAK1]) activation remained. Although fibrosis was greatly reduced, chamber dysfunction and dilation persisted. Induced myocyte knockdown of TGF-β type 2 receptor (TβR2) blocked all maladaptive responses, inhibiting myocyte and interstitial Smad and TAK1. Myocyte knockdown of TβR1 suppressed myocyte but not interstitial Smad, nor TAK1, modestly reducing fibrosis without improving chamber function or hypertrophy. Only TβR2 knockdown preserved capillary density after pressure overload, enhancing BMP7, a regulator of the endothelial-mesenchymal transition. BMP7 enhancement also was coupled to TAK1 suppression. Thus, myocyte targeting is required to modulate TGF-β in hearts subjected to pressure overload, with noncanonical pathways predominantly affecting the maladaptive hypertrophy/dysfunction.

Authors

Norimichi Koitabashi, Thomas Danner, Ari L. Zaiman, Yigal M. Pinto, Janelle Rowell, Joseph Mankowski, Dou Zhang, Taishi Nakamura, Eiki Takimoto, David A. Kass

×

Figure 7

Cardiomyocyte TβR1 knockdown does not prevent cardiac hypertrophy and remodeling in response to pressure overload.

Options: View larger image (or click on image) Download as PowerPoint
Cardiomyocyte TβR1 knockdown does not prevent cardiac hypertrophy and re...
(A). Representative M-mode echocardiogram after TAC, and temporal changes of FS and LV diastolic dimension. (B–D). Cardiac hypertrophy was not inhibited in TβR1cKD animals. *P < 0.05 vs. sham. (B) Heart weight/tibia length ratio. n = 8 (sham); 11 (TAC MCM); 9 (TAC TβR1FF); 10 (TAC TβR1cKD). (C) Representative WGA staining for CSA measurement. Scale bars: 50 μm. (D) Myocyte hypertrophy, as assessed by CSA. Averaged data from 400–800 cells per heart. n = 4 (sham); 7 (TAC MCM), 5 (TAC TβR1FF and TAC TβR1cKD). (E) Reduced myocardial but not perivascular fibrosis area in TβR1cKD mice. n = 4 (sham); 7 (TAC MCM), 5 (TAC TβR1FF and TAC TβR1cKD). *P < 0.05 vs. sham; †P < 0.05 vs. TAC TβR1FF. (F) Representative Western blot for Smad3 and TAK1 activation after TAC. (G) Representative phospho-Smad3 immunostaining in LV after 9-week TAC in TβR1cKD. Green, phospho-Smad3; red, sarcomeric α-actinin; blue, DAPI; white, WGA. White arrowheads, cardiomyocyte Smad3 activation. Scale bars: 50 μm. (H) mRNA expression levels, normalized to Gapdh and then to sham data, assessed by real-time RT-PCR. n = 7 (sham); 4 (TAC MCM); 5 (TAC TβR1FF); 8 (TAC TβR1cKD). *P < 0.05 vs. sham; †P < 0.05 vs. TAC TβR1FF; ‡P < 0.05 vs. TAC MCM.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts